Rauwolscine hydrochloride

CAS No. 6211-32-1

Rauwolscine hydrochloride( α-Yohimbine hydrochloride | Isoyohimbine hydrochloride )

Catalog No. M18915 CAS No. 6211-32-1

Rauwolscine, a natural alkaloid, is a specific and reversible α2-adrenergic receptor antagonist (Ki: 12 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 48 In Stock
25MG 35 In Stock
50MG 47 In Stock
100MG 65 In Stock
200MG Get Quote In Stock
500MG 152 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Rauwolscine hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Rauwolscine, a natural alkaloid, is a specific and reversible α2-adrenergic receptor antagonist (Ki: 12 nM).
  • Description
    Rauwolscine, a natural alkaloid, is a specific and reversible α2-adrenergic receptor antagonist (Ki: 12 nM). It is a stereoisomer of yohimbine, which potently antagonizes both α1- and α2-adrenergic receptors. Rauwolscine also acts as a receptor antagonist at the serotonin 5-HT2B receptor (Ki: 14.3 nM) and as a weak partial agonist at 5-HT1A (IC50: 1.3 μM). The α2-adrenergic receptor has diverse physiological functions and antagonists like rauwolscine have numerous applications, including the modulation of mood and behavior.(In Vitro):[3H]Rauwolscine binding to α2 adrenergic receptor is reversible, stcreospccific, and saturable. [3H]Rauwolscine specifically labels both the high and low affinity states of the α2 adrenergic receptor in brain membranes. [3H]Rauwolscine also behaves as a 5-HT1A receptor agonist and this conclusion is compatible with earlier functional studies, indicating that rauwolscine (as well as yohimbine) has agonistic properties at the level of 5-HT autoreceptors. When using [3H]5-HT as a radioligand, rauwolscine is determined to have relatively high affinity for the human receptor (Ki human=14.3 nM, Ki rat=35.8 nM). Saturation studies shows that the affinity of [3H]Rauwolscine is similar in mouse, rat, rabbit, dog (2.33-3.03 nM) except man where it is significantly higher (0.98 nM) .
  • In Vitro
    [3H]Rauwolscine binding to α2 adrenergic receptor is reversible, stcreospccific, and saturable. [3H]Rauwolscine specifically labels both the high and low affinity states of the α2 adrenergic receptor in brain membranes. [3H]Rauwolscine also behaves as a 5-HT1A receptor agonist and this conclusion is compatible with earlier functional studies, indicating that rauwolscine (as well as yohimbine) has agonistic properties at the level of 5-HT autoreceptors. When using [3H]5-HT as a radioligand, rauwolscine is determined to have relatively high affinity for the human receptor (Ki human=14.3 nM, Ki rat=35.8 nM). Saturation studies shows that the affinity of [3H]Rauwolscine is similar in mouse, rat, rabbit, dog (2.33-3.03 nM) except man where it is significantly higher (0.98 nM) .
  • In Vivo
    ——
  • Synonyms
    α-Yohimbine hydrochloride | Isoyohimbine hydrochloride
  • Pathway
    Cytoskeleton/Cell Adhesion Molecules
  • Target
    Microtubule/Tubulin
  • Recptor
    α2 adrenergic receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    6211-32-1
  • Formula Weight
    390.9
  • Molecular Formula
    C21H27ClN2O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 6 mg/mL 15.35 mM; H2O : 5 mg/mL 12.79 mM
  • SMILES
    Cl.[H][C@]12CC[C@H](O)[C@@H](C(=O)OC)[C@@]1([H])C[C@]1([H])N(CCc3c1[nH]c1ccccc31)C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Perry B D, U'Prichard D C. [3H] Rauwolscine (α-yohimbine): a specific antagonist radioligand for brain α2-adrenergic receptors[J]. European journal of pharmacology, 1981, 76(4): 461-464.
molnova catalog
related products
  • Entasobulin

    Entasobulin is an inhibitor of β-tubulin polymerization. It has a potential anticancer activity.

  • BRD70326

    A small molecule that inhibits tubulin polymerization.

  • Sovilnesib

    Sovilnesib is a kinesin-like protein KIF18A inhibitor (WO2020132648). Sovilnesib can be used for the research of cancer.